Previous studies have shown clinical benefits, but also an increased cost to treat patients with symptomatic severe aortic stenosis receiving transcatheter valve replacement (TAVR). There is little consensus regarding the cost-effectiveness for transcatheter versus surgical replacement.&nbsp; The present study was aimed to quantify the quality of life, adjusted survival for quality of life, resource utilization,<a href="https://solaci.org/en/2015/06/24/us-corevalve-cost-effectiveness-of-transcatheter-replacement-versus-surgical-replacement-in-high-risk-patients/" title="Read more" >...</a>

This study evaluated the safety and effectiveness of the CoreValve transcatheter valve replacement in patients with severe aortic stenosis with extreme risk for surgery.&nbsp; The primary end point was a composite of all-cause mortality and stroke at 24 months. The rate of death from any cause or cerebrovascular accident at 24 months was 38% for<a href="https://solaci.org/en/2015/06/24/corevalve-us-pivotal-trial-2-year-results-of-the-self-expanding-valve-on-inoperable-patients/" title="Read more" >...</a>

This study included 358 patients considered inoperable, randomized to TAVR with expandable balloon valve versus conservative treatment. The 5-year end points included all-cause mortality, cardiac mortality, re-hospitalization, and stroke. At 5 years, mortality from all causes was lower in TAVR group versus conservative treatment group (71.8% versus 93.6%, P &lt;0.0001). By dividing patients by STS<a href="https://solaci.org/en/2015/06/24/partner-cohort-b-5-year-results-of-a-balloon-expandable-valve-on-inoperable-patients/" title="Read more" >...</a>

The stroke is a leading complication of post transcatheter aortic valve implantation increasing up to 3 times the mortality of these patients. In the works performed neuroimaging new post, TAVR defects were observed in two-thirds of patients and this increases the risk of post clinical stroke.&nbsp; There is a missing data in the literature of<a href="https://solaci.org/en/2015/06/24/clean-tavi-transcatheter-aortic-valve-replacement-with-cerebral-protection/" title="Read more" >...</a>

TVT STS / ACC registrywas developed to obtain data from all patients undergoing percutaneous aortic valve replacement (TAVR) in the United States. The clinical outcome at 30 days was recently published (Macket al, JAMA 2013) but there are few data on the longer-term treatment that is already incorporated in clinical practice in the United States.The<a href="https://solaci.org/en/2015/06/24/american-registry-for-percutaneous-aortic-valve-replacementone-year-evolution-of-nearly-6000-patients/" title="Read more" >...</a>

The aim of this study was to compare percutaneous aortic valve replacement (TAVR) with the self-expanding Valve Core with conventional surgery in patients at high surgical risk. Patients with a valve area &lt; 0.8 cm2 , valvular index &le; 0.5 cm2 , a mean gradient of &nbsp;&gt; 40 mmHg or peak speeds above 4m /s<a href="https://solaci.org/en/2015/06/24/corevalve-superior-to-surgical-aortic-valve-replacement-in-high-risk-patients/" title="Read more" >...</a>

Background: Percutaneous aortic valve implantation (TAVI) is the treatment of choice for patients with severe aortic stenosis considered inoperable according to clinical outcomes at 12 months as reported in the PARTNER study, which demonstrated a reduction in mortality and an improvement in the quality of life for patients. However, the long term benefit of this<a href="https://solaci.org/en/2015/06/24/partner-cohort-b-clinical-events-at-3-years-follow-up-in-patients-with/" title="Read more" >...</a>